INS and type 1 diabetes mellitus: As previously reported (Svart et al., 2016), lipopolysaccharide infusion combined with insulin reduction resulted in profound glucagon responses in individuals with type 1 diabetes (Figure 1), resembling those seen in nondiabetic individuals (Rittig et al., 2015), and demonstrating intact glucagon responsiveness to systemic inflammation.